Discrepant results in the interpretation of HIV‐1 drug‐resistance genotypic data among widely used algorithms

The aim of this study was to assess the concordance on the interpretation of HIV‐1 drug‐resistance genotypic data by three widely used algorithms: Stanford University Database (SU), TruGene (Visible Genetics, Canada) (VG) and VirtualPhenotype (Virco, Belgium) (VP).

[1]  B. Larder,et al.  Quantitative detection of HIV-1 drug resistance mutations by automated DNA sequencing , 1993, Nature.

[2]  Bg Gazzard and.  British HIV Association (BHIVA) guidelines for the treatment of HIV-infected adults with antiretroviral therapy. , 2005, HIV medicine.

[3]  Henry J. Kaiser,et al.  Guidelines for the use of antiretroviral agents in HIV-infected adults and adolescents. Department of Health and Human Services and Henry J. Kaiser Family Foundation. , 1998, MMWR. Recommendations and reports : Morbidity and mortality weekly report. Recommendations and reports.

[4]  Soriano,et al.  Clinical and laboratory guidelines for the use of HIV-1 drug resistance testing as part of treatment management: recommendations for the European setting. The EuroGUidelines Group for HIV resistance. , 2001, AIDS.

[5]  P. Harrigan,et al.  Clinical utility of testing human immunodeficiency virus for drug resistance. , 2000, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[6]  S. Hammer,et al.  Antiretroviral drug resistance testing in adult HIV-1 infection: recommendations of an International AIDS Society-USA Panel. , 2000, JAMA.

[7]  K. Hertogs,et al.  Clinical and laboratory guidelines for the use of HIV-1 drug resistance testing as part of treatment management: recommendations for the European setting , 2001 .

[8]  J. Schapiro,et al.  Drug-resistance genotyping in HIV-1 therapy: the VIRAD APT randomi sed controlled trial , 1999, The Lancet.

[9]  A. Antinori,et al.  Usefulness of monitoring HIV drug resistance and adherence in individuals failing highly active antiretroviral therapy: a randomized study (ARGENTA) , 2002, AIDS.

[10]  Matthew J. Gonzales,et al.  Human Immunodeficiency Virus Reverse Transcriptase and Protease Sequence Database: an expanded data model integrating natural language text and sequence analysis programs , 2001, Nucleic Acids Res..

[11]  G. Satten,et al.  Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. , 1998, The New England journal of medicine.

[12]  Michael Ames,et al.  A randomized trial assessing the impact of phenotypic resistance testing on antiretroviral therapy , 2002, AIDS.

[13]  T. Merigan,et al.  A randomized study of antiretroviral management based on plasma genotypic antiretroviral resistance testing in patients failing therapy , 2000 .

[14]  H. Vahaboğlu,et al.  Activities of cefepime and five other antibiotics against nosocomial PER-1-type and/or OXA-10-type beta-lactamase-producing Pseudomonas aeruginosa and Acinetobacter spp. , 1998, The Journal of antimicrobial chemotherapy.

[15]  C. Petropoulos,et al.  Comparison of genotyping and phenotyping methods for determining susceptibility of HIV-1 to antiretroviral drugs , 2001, AIDS.

[16]  Pierre-Marie Girard,et al.  Phenotypic or genotypic resistance testing for choosing antiretroviral therapy after treatment failure: a randomized trial , 2002, AIDS.

[17]  M. Peeters,et al.  Patterns of Resistance Mutations to Antiretroviral Drugs in Extensively Treated HIV‐1‐Infected Patients With Failure of Highly Active Antiretroviral Therapy , 2001, Journal of acquired immune deficiency syndromes.

[18]  R. D’Aquila,et al.  Clinical use of genotypic and phenotypic drug resistance testing to monitor antiretroviral chemotherapy. , 2001, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[19]  V. Soriano,et al.  Spanish consensus conference on drug resistance testing in clinical practice. HIV drug resistance Spanish panel. , 1999, AIDS.

[20]  M A Fischl,et al.  Antiretroviral Therapy in Adults Updated Recommendations of the International AIDS Society–USA Panel , 2000 .

[21]  Paul Kellam,et al.  Convergent combination therapy can select viable multidrug-resistant HIV-1 in vitro , 1993, Nature.

[22]  K. Hertogs,et al.  HIV Drug Susceptibility and Treatment Response to Mega-Haart Regimen in Patients from the Frankfurt HIV Cohort , 2000, Antiviral therapy.

[23]  D. Richman.  Principles of HIV Resistance Testing and Overview of Assay Performance Characteristics , 2000, Antiviral therapy.

[24]  N. Shen,et al.  Extensive polymorphisms observed in HIV–1 clade B protease gene using high–density oligonucleotide arrays , 1996, Nature Medicine.

[25]  M. Lederman,et al.  Genotypic drug resistance and cause of death in HIV-infected persons who died in 1999. , 2001, Journal of acquired immune deficiency syndromes.

[26]  S. Hammer,et al.  The Relation between Baseline HIV Drug Resistance and Response to Antiretroviral Therapy: Re-Analysis of Retrospective and Prospective Studies Using a Standardized Data Analysis Plan , 2000, Antiviral therapy.

[27]  R. Haubrich,et al.  Phenotypic and Genotypic Resistance Assays: Methodology, Reliability, and Interpretations , 2001, Journal of acquired immune deficiency syndromes.

[28]  Lidia Ruiz,et al.  Clinical utility of HIV-1 genotyping and expert advice: the Havana trial , 2002, AIDS.

[29]  Brendan Larder,et al.  A Rapid Method for Simultaneous Detection of Phenotypic Resistance to Inhibitors of Protease and Reverse Transcriptase in Recombinant Human Immunodeficiency Virus Type 1 Isolates from Patients Treated with Antiretroviral Drugs , 1998, Antimicrobial Agents and Chemotherapy.

[30]  Jacob Cohen.  A Coefficient of Agreement for Nominal Scales , 1960 .